证券代码：002219 证券简称：新里程 新里程健康科技集团股份有限公司 投资者关系活动记录表 3 问：在当前医疗服务承压的大背景下，公司的发展战略是否有 调整？ 答：公司将持续夯实"医疗+医药"双轮驱动的产业格局，进一 步提升自身的品牌形象和市场影响力，促进公司高质量发展。 医疗服务板块，围绕"强省会、强中心、强学科"的经营思路， 持续推进等级医院建设及床位规模扩张，持续推进学科专业委员会 的作用与价值，持续推进有中国特色的管理式医疗，实现医疗机构利 润率和市场份额的稳步提高。 医药工业板块，通过自有研发、外延并购以及渠道改革，持续扩 大医药板块收入规模和利润贡献，推进医药领域新质生产力发展。 在做好现有业务经营的同时，公司加快推进控股股东优质资产 注入。同时公司也将积极推进外延式并购，寻找并收购医院及医药资 产，持续提升公司的业务规模和经营业绩。 问：2024 年医保收入占比及医保回款账期、坏账率情况？2025 年是否面临更大压力？ 答：2024 年医保收入占比 52%，医保回款中的月度部分账期为 1-2 个月，年度部分每年清算一次，综合账期约为 2-3 个月。医保结 算压力是存在的，医院将围绕医保政策从 ...

Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company has released its Q1 2025 report, showing a significant improvement in profitability due to the release of cost benefits [7] - The company achieved a total revenue of 8.315 billion yuan in Q1 2025, representing a year-on-year increase of 8.1%, and a net profit attributable to shareholders of 2.202 billion yuan, up 14.8% year-on-year [7] - The report highlights steady growth across major product categories and strong performance in online channels, with online revenue increasing by 43% year-on-year [7] - The company is expected to continue benefiting from both cost and reform dividends, driving market share growth through B2B and B2C strategies [7] Financial Performance Summary - Revenue projections for 2025-2027 are set at 29.7 billion, 32.8 billion, and 36.3 billion yuan, with year-on-year growth rates of 10%, 11%, and 11% respectively [7] - Net profit forecasts for the same period are 7 billion, 7.8 billion, and 8.6 billion yuan, with consistent growth rates of 11% [7] - The report indicates an expected increase in diluted EPS from 1.26 yuan in 2025 to 1.55 yuan in 2027, reflecting a positive trend in earnings [7]

本报讯(记者王宁)近日，由金信期货有限公司(以下简称"金信期货")主办，广州市白云区金融发展促进 会(以下简称"白云金促会")协办、中国金融期货交易所支持的"2025年股指期货及期权策略交流会"举 行。本次活动聚焦股指期货与期权工具的策略运用与市场前瞻，旨在加强业内交流，提升投资者对期货 市场的认知与实践能力，推动金融工具更好服务实体经济。 金信期货相关负责人表示，未来将持续深化"研究+服务"双轮驱动战略，助力投资者构建多维风险管理 体系，赋能资产配置新升级，共探投资新机遇。 金信期货总经理胡晓波表示，当前是金融市场加速发展的重要窗口期，投资者唯有持续提升专业素养、 熟练掌握金融工具，方能在复杂多变的市场环境中把握机遇、有效管理风险。"期货不仅是一种投资工 具，更是资产配置与风险控制的重要武器，期货市场的发展正为投资者提供更多多样化需求。" 金信期货资管部总经理朱曙围绕"股指期权基础知识及应用实践"展开讲解，系统介绍了股指期权的结构 机制、交易策略及实战应用，通过结合典型案例，为与会者搭建起期权交易的理论与实践框架。朱曙擅 长通过"宏观博弈、全天候套利"的投资策略来获取回报，追求风险与收益的相对平衡，其凭借深 ...

按产品结构划分，2024年，莫高股份葡萄酒业务实现营业收入6055.64万元，同比下降17.41%；药品业 务实现营业收入6712.11万元，同比增长35.71%；降解材料及制品业务实现营业收入1.11亿元，同比增 长114.56%，新膜袋业务实现营业收入7371.18万元。 2024年，莫高股份紧盯年初PBAT（生物降解聚酯）价格回暖趋势，适时开机生产，稳定市场份额；研 发新品延伸价值链，总结全降解地膜试验确定配方，推动全降解膜袋专用料等产品的市场销售，降解材 料及制品营业收入大幅增加。 药品方面，莫高股份改造复方甘草片片剂、口服液生产线，根据市场和行业情况，灵活调整产品价格， 抢抓机遇全力生产销售药品，药品营业收入大幅增加。 本报讯 （记者刘欢）4月29日，甘肃莫高实业发展股份有限公司（以下简称"莫高股份"）发布2024年年 度报告。公司2024年实现营业收入3.28亿元，同比增长65.38%；扣除与主营业务无关的业务收入和不具 备商业实质的收入后的营业收入3.12亿元，同比增长78.98%。 公告显示，未来，莫高股份将坚持"开放的莫高、走出去的战略"，加快实施"葡萄酒+降解材料"双轮驱 动战略，推进葡萄 ...

Financial Performance - In 2024, the company achieved operating revenue of 1.8 billion yuan, a year-on-year increase of 3.13% compared to 1.74 billion yuan in 2023 [1] - The net loss attributable to shareholders was 267.17 million yuan, a decrease of 19.27% from a loss of 224.01 million yuan in 2023 [1] - The net cash flow from operating activities was -323.72 million yuan, representing a decline of 78.48% compared to -181.38 million yuan in 2023 [1] Business Segments - The company executed a "consumer electronics + new energy" dual-drive strategy, with consumer electronics revenue stabilizing and increasing by 70.32% to 466 million yuan [2] - New energy business revenue accounted for 30% of total revenue, growing by 25.73%, with lithium battery components making up 27.99% of this segment [2] Production and R&D - The subsidiary Jiangsu Jiashe's new production lines for PC displays and modules commenced operations in April 2024, with a monthly capacity of 50,000 units for displays and 80,000 units for modules [2] - The company invested 75.62 million yuan in R&D in 2024, representing 4.21% of operating revenue, and holds a total of 422 patents [2] Future Outlook - The company aims to transform into a new materials-focused listed company over the next 3 to 5 years, emphasizing high-performance materials in thermal management, high-end bonding, and electrochemical applications [5] - The ongoing dual-drive strategy is expected to enhance production efficiency and market share through resource integration, process innovation, and cost reduction [5]

Investment Rating - The investment rating for the company is "Buy" with a target price of 60.06 RMB [8][9]. Core Views - The company reported a strong start in Q1 2025, with revenue growth accelerating. For 2024, the company achieved revenue of 8.98 billion RMB, a year-on-year increase of 9.7%, and a net profit of 700 million RMB, up 19.8% year-on-year. The Q1 2025 revenue was 2.61 billion RMB, reflecting a year-on-year growth of 36.5% [1][5]. - The growth in revenue and profit is attributed to the acceleration in consumer goods and the consolidation of GRI in the medical business. The consumer goods segment is showing improvement, and the medical segment has effectively absorbed high base pressures [1][2]. Summary by Sections Consumer Goods - In 2024 and Q1 2025, the health lifestyle consumer goods segment achieved revenues of 4.99 billion RMB and 1.34 billion RMB, respectively, with year-on-year growth of 17.1% and 28.8%. Key product categories such as cotton soft towels and sanitary napkins saw significant growth, with revenues increasing by 31% and 18% respectively in 2024 [2]. Medical Supplies - The medical supplies segment reported revenues of 3.91 billion RMB in 2024 and 1.25 billion RMB in Q1 2025, with year-on-year growth of 1.1% and 46.3%. The infection protection products faced a high base pressure, with a revenue decline of 61.2% in 2024, but this pressure is gradually being absorbed [3]. Financial Metrics - The gross margin for 2024 decreased by 1.7 percentage points to 47.3%, primarily due to rising raw material costs. The expense ratio also decreased by 1.7 percentage points to 35.5%, benefiting from revenue growth diluting expenses [4]. - The company has adjusted its revenue forecasts for 2025-2026 upwards, with expected net profits of 1.06 billion RMB, 1.30 billion RMB, and 1.59 billion RMB for 2025, 2026, and 2027 respectively. The target price is based on a 33 times PE ratio for 2025 [5][9].

Investment Rating - The investment rating for the company is "Buy" with a target price of RMB 60.06 [8][9]. Core Insights - The company reported a revenue of RMB 8.98 billion in 2024, a year-on-year increase of 9.7%, and a net profit of RMB 700 million, up 19.8% year-on-year. The revenue exceeded previous expectations, while profit was slightly below due to an asset impairment loss of approximately RMB 240 million [1]. - In Q1 2025, the company achieved a revenue of RMB 2.61 billion, representing a year-on-year growth of 36.5%, and a net profit of RMB 250 million, also up 36.3% year-on-year. This growth is attributed to accelerated consumer goods sales and the consolidation of GRI in the medical segment [1]. - The company is expected to benefit from a dual growth strategy in consumer and medical sectors, with a strong growth momentum anticipated in 2025 [1]. Summary by Sections Consumer Products - The health and lifestyle consumer products segment generated revenues of RMB 4.99 billion in 2024 and RMB 1.34 billion in Q1 2025, with year-on-year growth rates of 17.1% and 28.8%, respectively. Key product categories such as cotton soft towels and sanitary napkins saw double-digit growth [2]. Medical Supplies - The medical supplies segment reported revenues of RMB 3.91 billion in 2024 and RMB 1.25 billion in Q1 2025, with year-on-year growth of 1.1% and 46.3%, respectively. The high base effect from infection prevention products is gradually being digested, while regular products showed strong growth [3]. Financial Metrics - The gross margin for 2024 decreased by 1.7 percentage points to 47.3%, primarily due to rising raw material costs. The expense ratio also decreased by 1.7 percentage points to 35.5%, benefiting from revenue growth [4]. - The company has adjusted its revenue forecasts for 2025-2026 upwards, with expected net profits of RMB 1.06 billion, RMB 1.30 billion, and RMB 1.59 billion for 2025, 2026, and 2027, respectively. The corresponding EPS is projected to be RMB 1.82, RMB 2.23, and RMB 2.73 [5].

公司24 年收入/归母净利40.27/4.29 亿元（yoy+0.4%/-35.6%），利润端低于Wind 一致预期（预期5.63 亿 元），我们推测主因行业需求阶段性放缓及竞争加剧等短期扰动，叠加公司短期强化人员及设备投入。 公司1Q25 收入/归母净利10.93/1.50 亿元（yoy+11.7%/-4.0%，qoq+29.3%/+1824.0%），公司业绩已呈边 际提速态势。公司同日发布2025 年员工持股计划（草案），其公司层面的业绩考核指标（解锁比例 100%）为25/26/27 年公司收入或净利润较24 年业绩基数增长率不低于10%/20%/30%，对应25/26/27 年 公司收入或净利润同比增速不低于10.0%/9.1%/8.3%，彰显长期发展信心。 盈利预测与估值 考虑屈光新术式推广及人员设备投入强化对于销售费用率和管理费用率的影响，我们预计25-27 年EPS 为0.57/0.66/0.76 元（相比25/26 年前值下调22%/22%）。公司诊疗实力过硬且服务网络积极扩张，给予 公司25 年40xPE（可比公司Wind 一致预期均值34x），对应目标价22.87 元（前值27.03元，对 ...

Core Viewpoint - The company reported a mixed performance in Q1 2025, with revenue growth but a decline in net profit, indicating potential challenges in profitability despite revenue increases [1][2]. Financial Performance - In Q1 2025, the company achieved revenue of 595 million yuan, a year-on-year increase of 10.26% [1]. - The net profit attributable to shareholders was 68 million yuan, down 8.21% year-on-year, while the net profit excluding non-recurring items was 53 million yuan, a decrease of 8.61% [1]. - The gross margin for Q1 2025 was 29.91%, a decline of 0.11 percentage points year-on-year, primarily due to rising costs of raw materials [2]. - The company’s expense ratio increased to 19.01%, up 1.68 percentage points year-on-year, with sales expenses at 13.36%, management expenses at 4.05%, R&D expenses at 1.98%, and financial expenses at -0.37% [2]. - The net profit margin for Q1 2025 was 11.34%, down 2.28 percentage points year-on-year, while the net profit margin excluding non-recurring items was 8.96%, a decrease of 1.85 percentage points [2]. Growth Drivers - The company is focusing on channel expansion through fast-growing avenues such as snack wholesale, membership stores, and e-commerce, with product innovation expected to drive growth [2]. - Key products like quail eggs, soft-boiled quail eggs, and short-shelf-life tofu are being pushed for wider distribution, which is anticipated to contribute to revenue growth [2]. Future Projections - Revenue forecasts for 2025-2027 are 2.896 billion, 3.436 billion, and 4.083 billion yuan, representing year-on-year growth rates of 20.08%, 18.63%, and 18.85% respectively [3]. - Expected net profits for the same period are 316 million, 372 million, and 443 million yuan, with growth rates of 8.53%, 17.61%, and 19.11% respectively [3]. - The projected price-to-earnings ratios for 2025-2027 are 18.4, 15.6, and 13.1 times [3].

Core Insights - The company achieved a revenue of 5.304 billion yuan in FY24, representing a year-on-year increase of 28.89%, and a net profit attributable to shareholders of 640 million yuan, up 26.53% year-on-year [1] - The company is experiencing significant growth in the konjac product category, with a strong overseas expansion strategy [2][3] - The gross margin has faced pressure, but cost control measures have improved [4][5] - The company has initiated a brand strategy focusing on "Big Demon King" and "Egg Emperor," which is showing early signs of success [6] - Revenue forecasts for 2025-2027 have been adjusted upward, indicating positive growth expectations [7] Financial Performance - FY24 revenue breakdown: spicy snacks (1.962 billion yuan, +32.36%), baked potato products (1.158 billion yuan, +17.31%), deep-sea snacks (675 million yuan, +9.10%), egg snacks (580 million yuan, +81.87%), nuts (484 million yuan, +81.50%), konjac jelly pudding (301 million yuan, +39.10%), and other income (144 million yuan, -36.09%) [2] - Q1 2025 revenue reached 1.537 billion yuan, a year-on-year increase of 25.69%, with net profit attributable to shareholders at 178 million yuan, up 11.64% [1] Product and Channel Analysis - The konjac product line, particularly the "Big Demon King" brand, has driven significant growth, with a record-breaking single product sales milestone [2] - Revenue by channel in FY24: direct sales (188 million yuan, -43.72%), distribution and other channels (3.956 billion yuan, +34.01%), and e-commerce (1.159 billion yuan, +39.95%) [2] - The company aims to replicate its success in overseas markets, with over 80% of international sales currently coming from Thailand [3] Cost and Profitability - Gross margins for FY24, Q4 2024, and Q1 2025 were 30.69%, 27.62%, and 28.47%, respectively, reflecting a decline due to the rapid growth of lower-margin channels [4] - The company has improved its cost control, with sales, management, R&D, and financial expense ratios showing a decrease in FY24 compared to the previous year [4] Strategic Initiatives - The company has launched a category brand strategy, focusing on high-potential products like konjac and quail eggs, aiming for a dual-driven growth model of "products + channels" [6] - The strategic transformation has already led to the development of two major hit products, indicating a successful execution of the brand strategy [6] Investment Outlook - Revenue forecasts for 2025 and 2026 have been revised upwards to 6.594 billion yuan and 7.968 billion yuan, respectively, with a new forecast for 2027 at 9.431 billion yuan [7] - EPS estimates for 2025 and 2026 have also been increased to 3.10 yuan and 3.86 yuan, respectively, with a new estimate of 4.52 yuan for 2027 [7]